Intuitive Surgical Down 40%: The Headwinds Are Temporary, the Multiple Isn't

Intuitive Surgical rose about 2.4% today while the market dipped, a small bounce in a stock that has lost roughly 40% from its highs. That bounce is noise. The useful thing to know is why the stock fell a third this year, which of the reasons are temporary, and whether the drop finally made the price an edge. On the evidence, two of the three reasons are temporary, but the price still isn't cheap.

The beat that triggered a sell-off

The de-rating has a clean trigger. In mid-July Intuitive reported Q2 2026 revenue of $2.89 billion, up 19%, and adjusted EPS of $2.80, about $0.30 ahead of estimates. Shares fell 11–14% anyway. The market wanted an upgrade it didn't get: management maintained full-year da Vinci procedure growth guidance at 13.5%–15.5% and said results would land near the midpoint, closer to 14.5% than the roughly 15.3% analysts had penciled in. As one analyst at William Blair put it, a reiterated guide "didn't quite pass the mark for a beat-and-raise".

That reaction makes sense only if you take the slowdown at face value. Da Vinci procedure growth eased to about 15% in the second quarter from 17% in the first, and U.S. growth slipped to 12% from 14%. Beneath those two numbers sit three distinct forces, and they are not equivalent.

Two headwinds that are temporary

The first is a policy cliff. Intuitive attributes parts of the U.S. slowdown to patients pushing off treatment and switching insurance coverage after enhanced Affordable Care Act premium subsidies expired. That is a coverage change, not a loss of the underlying disease or demand; management's read is that the procedures are delayed, not gone. A subsidy cliff is a one-year arithmetic problem that laps itself.

The second is tariffs, and it is pre-quantified. Intuitive's full-year non-GAAP gross margin guidance of 68%–69% of revenue already bakes in about a 1% hit from tariffs, and the quarter itself included a $28 million net-of-tax refund from tariff litigation. This is a friction cost sitting on top of a business that still prints a 66% gross margin and a 31% operating margin.

The third headwind — GLP-1 weight-loss drugs eating into bariatric surgery — is real but partial. Weight-loss procedures are one slice of da Vinci's case volume, not the platform's whole demand base.

The structure that held up

Now weigh what a 40% de-rating had to ignore. Revenue is growing 19%, operating profit rose about 29%, and the installed base of da Vinci systems hit 11,710, up 12%, with Ion lung robotics at 1,096, up 21%. That installed base is a recurring-revenue flywheel: instruments and accessories, the consumables attached to every procedure, grew 18%. Margins, cash generation, and the balance sheet all came through intact — free cash flow grew 61% over the trailing year, and the company sits on $8.6 billion in cash and investments with no net debt. This is not a business the market caught cheating; the numbers support forward earnings power.

The one real risk the market is right about

That is what makes the sell-off a genuine divergence story, but not a clean one. The de-rating is not only noise, because one of the headwinds deserves the structural label the market applied. Competition in China is rising, and the da Vinci-era monopoly is ending. The rational-capitalist critique that "the monopoly is ending" is the part of the narrative that forward math cannot refute on current estimates alone. If Chinese systems and GLP-1 shift enough case volume, procedure growth settling into the low-to-mid teens — rather than high teens — is a real scenario, and it is the one the market is now pricing.

The price still isn't the edge

Here is where the buy-the-dip reflex fails. Even after losing a third of its value and sitting near the low end of its 52-week range, Intuitive still trades at roughly 42x trailing earnings, close to 49x forward earnings, with a PEG near 2 and an enterprise value around 30x EBITDA. A $133 billion market cap for a 19%-grower is not a fallen value stock; it is a premium quality compounder that got de-rated from very expensive to merely expensive.

The disciplined read is a watch-and-verify, not a blind buy. The math held up through the sentiment slump, so the story isn't broken. But at these multiples the market is not paying you to be right about a temporary-headwind recovery — an 11%–14% single-day flush already removed the froth, not the central risk. The variable that decides the case is whether annual procedure growth holds the mid-teens as the subsidy cliff laps and China competition scales, or whether it decelerates into a structural plateau. If the growth holds, forward earnings power is intact and the de-rating was sentiment. If it doesn't, the multiple has further to fall. The evidence says wait for that number to resolve before that conviction earns a price.